triple negative breast cancer

[Molecular Therapy-Nucleic Acids] Investigators review the current findings on the potential of circular RNAs (circRNAs) as a diagnostic, prognostic, and therapeutic biomarker for TNBC, and discuss the current limitations and future directions of TNBC-associated circRNAs, which can facilitate the translation of experimental research into clinical application.

[Journal of Cancer Research and Clinical Oncology] The effect of combined PD-1/PD-L1 and extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor treatment was investigated of cell growth and intracellular impact of breast cancer cell lines.

[BMC Cancer] BRE-AS1 was downregulated in TNBC, while miR-21 was highly expressed in TNBC. Low expression levels of long non-coding RNA BRE-AS1 and high expression levels of miR-21 were significantly correlated with unfavorable survival outcomes.

[Molecular Cell] Researchers interrogated the function of RNA-binding proteins (RBP) in cancer using pooled CRISPR-Cas9 screening and identified 57 RBP candidates with distinct roles in supporting MYC-driven oncogenic pathways in TNBC cells.

[Oncogene] Despite its well-documented inhibitory effects, higher PD-1 expression in tumor-infiltrating lymphocytes was significantly associated with longer survival in triple-negative breast cancer patients.

[Nature] Researchers generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary TNBC patient-derived xenografts, revealing the nature of copy number alteration-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy.